IFP Advisors’s AYTU BioPharma AYTU Stock Holding History

IFP Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-110	Closed	-$297	–	3068
2023 Q3	$297	Hold	110	–	–	﹤0.01%	3156
2023 Q2	$176	Hold	110	–	–	﹤0.01%	3324
2023 Q1	$425	Hold	110	–	–	﹤0.01%	3200
2022 Q4	$15K	Buy	110 +50	+83%	+$188	﹤0.01%	3093
2022 Q3	$8K	Hold	60	–	–	﹤0.01%	3751
2022 Q2	$8K	Hold	60	–	–	﹤0.01%	3507
2022 Q1	$8K	Hold	60	–	–	﹤0.01%	3507
2021 Q4	$2K	Buy	60 +30	+100%	+$1.3K	﹤0.01%	2743
2021 Q3	$2K	Buy	30 +20	+200%	+$1.5K	﹤0.01%	2814
2021 Q2	$1K	Buy	+10	New	+$1.17K	﹤0.01%	2863
2020 Q4	–	Sell	-15	Closed	-$2.73K	–	2936
2020 Q3	$4K	Hold	15	–	–	﹤0.01%	2245
2020 Q2	$5K	Hold	15	–	–	﹤0.01%	2060
2020 Q1	$5K	Buy	+15	New	+$2.9K	﹤0.01%	2037
2018 Q3	–	Hold	0	–	–	–	3819
2018 Q2	–	Hold	0	–	–	–	3871

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IFP Advisors's AYTU Position: Q4 2023 in Review

IFP Advisors sold out of AYTU BioPharma (AYTU) in Q4 2023, closing a stake of 110 shares — an estimated $297 sold.

IFP Advisors first reported a position in AYTU in Q1 2020 and held it in 13 quarters. The position peaked at $15K in Q4 2022. 22 funds tracked by Wall St. Rank hold AYTU as of Q4 2023.

IFP Advisors reported no remaining AYTU BioPharma position as of Q4 2023 after selling out during the quarter.
IFP Advisors sold 110 AYTU BioPharma shares in Q4 2023, an estimated $297.
IFP Advisors first reported a position in AYTU BioPharma in Q1 2020 and held it in 13 quarters.
IFP Advisors's AYTU BioPharma position peaked at $15K in Q4 2022.
22 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2023.

Based on IFP Advisors's 13F filing for Q4 2023, filed 9 Jan 2024.